MetaCap

Context Therapeutics (CNTX) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals (CTXR) has outperformed Context Therapeutics (CNTX) over the past year, losing 55.4% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -98.8% for CTXR. Context Therapeutics is the larger company by market cap ($14.7 million vs $14.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTX-85.32%CTXR-55.39%
+223%+61%-100%
Nov 21, 20251 yearNov 20, 2026
CNTX-96.73%CTXR-98.81%
+16%-44%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTX versus CTXR key metrics
MetricCNTXCTXR
Share price$0.16$0.5085
Market cap$14.70M$13.96M
1-day change-5.10%+2.27%
YTD return-89.12%-34.56%
1-year return-85.32%-55.39%
5-year return-96.86%-98.79%
EPS (TTM)$-0.46$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-36.12M$-39.74M
52-week high$3.62$1.54
52-week low$0.153$0.37
Distance from 52-week high-95.58%-66.98%
Analyst consensusnonenone
Avg. price target upside+2418.75%+686.63%
Average volume1.42M275.44K
Shares outstanding91.88M27.45M
Employees1523
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTXR has outperformed CNTX by 29.9 percentage points over the past year.

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

CNTX vs CTXR FAQ

Which is bigger, Context Therapeutics or Citius Pharmaceuticals?

Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.96M for Citius Pharmaceuticals (CTXR).

Which stock has performed better over the past year, CNTX or CTXR?

CTXR returned -55.39% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.

Are Context Therapeutics and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons